China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerPRNewsWire • 03/28/24
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyPRNewsWire • 03/26/24
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric CancerPRNewsWire • 03/26/24
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment SettingPRNewsWire • 03/22/24
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in JapanPRNewsWire • 03/03/24
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology TherapeuticsPRNewsWire • 02/15/24
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder CancerPRNewsWire • 01/31/24
Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas PharmaBusiness Wire • 01/04/24
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage EngagerPRNewsWire • 12/28/23
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged ChildrenPRNewsWire • 12/17/23
Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay TherapeuticsPRNewsWire • 12/13/23
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with MenopausePRNewsWire • 12/10/23
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell TherapiesBusiness Wire • 11/30/23
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone TherapyPRNewsWire • 11/29/23